CN1450908A - 神经毒性寡聚体 - Google Patents

神经毒性寡聚体 Download PDF

Info

Publication number
CN1450908A
CN1450908A CN01813312A CN01813312A CN1450908A CN 1450908 A CN1450908 A CN 1450908A CN 01813312 A CN01813312 A CN 01813312A CN 01813312 A CN01813312 A CN 01813312A CN 1450908 A CN1450908 A CN 1450908A
Authority
CN
China
Prior art keywords
tyrosine
antibody
disease
compound
crosslinked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01813312A
Other languages
English (en)
Chinese (zh)
Inventor
A·布什
R·彻尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
General Hospital Corp
Original Assignee
Prana Biotechnology Ltd
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd, General Hospital Corp filed Critical Prana Biotechnology Ltd
Publication of CN1450908A publication Critical patent/CN1450908A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
CN01813312A 2000-06-28 2001-06-28 神经毒性寡聚体 Pending CN1450908A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21477900P 2000-06-28 2000-06-28
US60/214,779 2000-06-28
US24217700P 2000-10-23 2000-10-23
US60/242,177 2000-10-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2008101298934A Division CN101411876B (zh) 2000-06-28 2001-06-28 神经毒性寡聚体

Publications (1)

Publication Number Publication Date
CN1450908A true CN1450908A (zh) 2003-10-22

Family

ID=26909346

Family Applications (2)

Application Number Title Priority Date Filing Date
CN01813312A Pending CN1450908A (zh) 2000-06-28 2001-06-28 神经毒性寡聚体
CN2008101298934A Expired - Fee Related CN101411876B (zh) 2000-06-28 2001-06-28 神经毒性寡聚体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2008101298934A Expired - Fee Related CN101411876B (zh) 2000-06-28 2001-06-28 神经毒性寡聚体

Country Status (10)

Country Link
US (2) US7618634B2 (https=)
EP (1) EP1296705B1 (https=)
JP (1) JP2004501204A (https=)
CN (2) CN1450908A (https=)
AU (2) AU6882801A (https=)
CA (1) CA2413354C (https=)
DK (1) DK1296705T3 (https=)
ES (1) ES2389811T3 (https=)
NZ (1) NZ523428A (https=)
WO (1) WO2002000245A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006014638A2 (en) * 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
DK1984344T3 (da) 2005-12-29 2013-01-14 Lexicon Pharmaceuticals Inc Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US20090246191A1 (en) * 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2011064225A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment
JP2013521233A (ja) 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
KR102759003B1 (ko) * 2018-05-15 2025-01-23 보오슈 앤드 롬 인코포레이팃드 수 추출 가능한 안과용 디바이스
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
DE102019129221B4 (de) 2019-10-29 2022-05-12 Chiracon Gmbh Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
KR20230128606A (ko) * 2022-02-28 2023-09-05 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물
CN117024554A (zh) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 一种Aβ1-42寡聚体存储液的制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
EP1296705A4 (en) 2005-04-20
EP1296705B1 (en) 2012-06-13
US20040013680A1 (en) 2004-01-22
JP2004501204A (ja) 2004-01-15
CA2413354A1 (en) 2002-01-03
NZ523428A (en) 2008-03-28
HK1131745A1 (en) 2010-02-05
CA2413354C (en) 2014-04-01
AU6882801A (en) 2002-01-08
US7618634B2 (en) 2009-11-17
AU2001268828B2 (en) 2006-07-06
CN101411876A (zh) 2009-04-22
AU2001268828C1 (en) 2006-12-14
US20090297538A1 (en) 2009-12-03
WO2002000245A1 (en) 2002-01-03
ES2389811T3 (es) 2012-10-31
US8318171B2 (en) 2012-11-27
DK1296705T3 (da) 2012-09-17
CN101411876B (zh) 2013-01-16
EP1296705A1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
CN101411876B (zh) 神经毒性寡聚体
US20200190173A1 (en) Immunotherapy for Clearing Pathological Tau Conformers
EP1497321B1 (en) Immunological methods and compositions for the treatment of alzheimer's disease
CN102946899B (zh) 药物组合物
AU2001268828A1 (en) Neurotoxic oligomers
CN101420983B (zh) 包含超分子抗原构建体的组合物和方法
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson's disease
MX2010013648A (es) Compuestos para tratar enfermedades.
HK1131745B (en) Neurotoxic oligomers
JP4934433B2 (ja) 超分子コンストラクトを含む方法および組成物
HK1231408B (en) Pharmaceutical composition
HK1164127B (en) Pharmaceutical composition
HK1072947B (en) Immunological methods and compositions for the treatment of alzheimer's disease
HK1127486A1 (en) Therapeutic vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication